Compassionate use of polatuzumab vedotin in patients with relapsed/refractory diffuse large B-cell lymphoma: report of one case and review of literature
10.3760/cma.j.cn115356-20201020-00249
- VernacularTitle:复发难治弥漫大B细胞淋巴瘤患者接受polatuzumab vedotin同情用药一例并文献复习
- Author:
Jianqiu WU
1
;
Weiyan TANG
;
Yue TENG
;
Xueting FAN
;
Jifeng FENG
Author Information
1. 江苏省肿瘤医院肿瘤内科，南京 210000
- Keywords:
Lymphoma, large B-cell, diffuse;
Compassionate use;
Polatuzumab vedotin
- From:
Journal of Leukemia & Lymphoma
2021;30(7):411-414
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of polatuzumab vedotin (pola) in treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).Methods:The clinical data of 1 DLBCL patient receiving multiple treatments in Jiangsu Cancer Hospital in May 2016 were retrospectively analyzed, and the related literature was reviewed.Results:The patient, a 57-year-old male, was diagnosed with DLBCL in May 2016. Since June 2016, he had received treatments with four lines including anti-CD20 monoclonal antibody combined with chemotherapy, chemotherapy only and chimeric antigen receptor T cell (CAR-T). However, the disease relapsed or progressed after all treatments. Therefore, the patient had received 6 cycles of pola combined with rituximab since December 2019. Unexpected adverse events were not found during the treatment. The evaluation of clinical efficacy was complete remission after the end of treatment. The progression-free survival time was more than 13 months with follow-up until January 2021.Conclusion:Pola initially shows good efficacy and safety in treatment of patients with relapsed/refractory DLBCL.
